BPC-157 has been studied in people, but the evidence does not establish the healing, safety or combination benefits often claimed online. Most BPC-157 myths start when a small finding grows into a much bigger promise. A rat injury study becomes a claim about human recovery; two people reporting no side effects becomes “there are none.”
The useful question is what each study actually tested. A real paper can still be the wrong evidence for the claim beside it.
BPC-157 myths: how the grades work
Supported means the evidence backs the claim as written. Partly means one piece holds up. Not supported means the claim goes beyond the findings; unknown means the comparison hasn't been settled. An unsupported claim isn't automatically proof that a treatment fails.
1. “It heals tendons in people.”
Not supported: tendons connect muscles to bones, and the familiar papers studied them in rats. Staresinic and colleagues, Journal of Orthopaedic Research, 2003, examined surgically cut Achilles tendons, the bands behind the ankles; Chang and colleagues, Journal of Applied Physiology, 2011, examined rat tendon tissue and cells grown in a lab. Those experiments reported changes in repair or cell behavior, but neither tested recovery in a person. Small human reports address other questions, as the BPC-157 human-studies inventory explains; they don't establish that BPC-157 heals human tendons.
2. “It's natural because it comes from your stomach.”
Partly: the stomach connection belongs to its research history. Sikirić and colleagues' 1993 paper in Journal de Physiologie, Paris described a stomach-juice protein and a fragment containing 15 amino acids, the building blocks of proteins. BPC-157 preparations use a synthetic peptide, meaning a manufactured short chain of those building blocks, rather than a stomach extract. The origin of that chain cannot establish the safety of a manufactured preparation, the amount given or its route into the body.
3. “It has no side effects.”
Not supported: a 2025 pilot by Lee and Burgess in Alternative Therapies in Health and Medicine reported no side effects in two previously exposed adults during three days of observation around infusions into a vein. Two people cannot reveal uncommon reactions or the effects of months of use. As of September 10, 2026, the day this article was written, the Food and Drug Administration (FDA) review dated May 11, 2026, prepared for the July meeting still described insufficient clinical safety information. The BPC-157 side-effects guide separates reported reactions from established risks.
4. “A capsule works as well as a shot.”
Unknown: Grgic and colleagues' 2016 rat experiment, European Journal of Pharmacology, studied BPC-157 in drinking water or by injection after creating an abnormal connection between the bowel and bladder. That model does not establish equal absorption or equal outcomes from capsules and injections in people. Surviving stomach acid, reaching the bloodstream and helping a particular condition are separate questions. The oral BPC-157 explainer covers the route comparison; a capsule being convenient doesn't settle it.
5. “The July FDA review settled its status.”
Not supported: As of September 10, 2026, the day this article was written, FDA's July 23–24 meeting record concerns a compounding ingredient list and explicitly describes committee recommendations as nonbinding. BPC-157 is not FDA-approved, and the compounded formulation offered here is not FDA-approved either. Compounding means preparing a medication for a particular prescription, and the explanation of why BPC-157 is not FDA-approved distinguishes ingredient-list decisions from approval of a finished drug. A licensed provider may still prescribe a compounded formulation when applicable requirements are met; that decision is between the patient and the doctor.
6. “If I can buy it online, it must be a lawful medicine.”
Not supported: being offered a product establishes that someone is selling it, not that its medical supply route meets the rules. As checked September 10, 2026, FDA's compounding requirements cover ingredient eligibility and documentation as well as who prepares the medicine. A prescription does not remove those separate pharmacy obligations, and a vial labeled for laboratory use isn't evidence of a clinical review. The peptide legality guide explains why the product, prescription and pharmacy all matter.
7. “Adding TB-500 makes it twice as effective.”
Not supported. As of September 10, 2026, the day this article was written, a July 23, 2026 study by Biçer and colleagues in Joint Diseases and Related Surgery found no added benefit from the combination in 32 rats assessed four weeks after Achilles tendon repair. The four groups received BPC-157, another peptide called TB-500, both, or neither. Wolverine combines these two peptides in one prescription, but the experiment did not test Promise's blend or establish results in people; the BPC-157 and TB-500 comparison explains their differences.
8. “Sports testing won't pick it up.”
Not supported. As of September 10, 2026, the day this article was written, Mazzarino and colleagues' Analyst paper, first published June 18, 2026, describes laboratory testing for 54 substances, including BPC-157, in dried blood spots and liquid blood samples. That doesn't tell us which tests a particular sports program uses. Separately, the World Anti-Doping Agency (WADA) list effective January 1, 2026 names BPC-157 under S0, its category for non-approved substances, and prohibits it in and out of competition; the BPC-157 drug-testing guide explains this separate rulebook.
9. “The arginate form is better.”
Unknown: arginate describes a salt form that pairs the peptide with arginine, an amino acid, not a result from a treatment comparison. The often-cited He and colleagues study, Frontiers in Pharmacology, 2022, followed injected BPC-157 through rats and dogs; it did not compare arginate with another salt form, acetate, or establish which works better in humans. No published human comparison establishes an arginate advantage, as the BPC-157 arginate guide explains. A claim about stability needs evidence of its own before it can support a claim about treatment.
10. “It fixes IBS or Crohn's disease.”
Not supported: IBS, or irritable bowel syndrome, involves recurring abdominal pain and changes in bowel habits; Crohn's disease involves ongoing inflammation in the digestive tract. The FDA review described above found no clinical studies for Crohn's disease and assessed limited evidence for ulcerative colitis, a different inflammatory bowel condition. That evidence included a 53-person study reported in an abstract, a short study summary, with about half receiving BPC-157. Human gut research therefore exists, but it does not establish treatment for IBS or Crohn's, and rat gut-injury experiments cannot fill that gap.
Does BPC-157 really work? What the grades mean
The evidence leaves room for a conversation, not a prediction. At Promise, a licensed provider reviews every request, and not everyone qualifies. The review weighs the person's history, current medicines, goals and other treatment options against these limits.
A prescription provides an accountable clinical decision and a pharmacy record of the preparation. It cannot turn a rat experiment into a human result, make a blend's benefit certain or supply the long-term safety data that are still missing.